Skip to main content
Peter Kaiser, MD, Ophthalmology, Cleveland, OH

PeterKKaiserMD

Ophthalmology Cleveland, OH

Retinal Disease

Chaney Family Endowed Chair in Ophthalmology Research Professor of Ophthalmology, Cole Eye Institute, Cleveland, OH

Dr. Kaiser is on Doximity

As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.

  • Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
  • Connect with colleagues in the same hospital or clinic.
  • Read the latest clinical news, personalized to your specialty.

See Dr. Kaiser's full profile

Already have an account?

  • Office

    9500 Euclid Ave
    Cleveland, OH 44195
    Phone+1 800-223-2273

Education & Training

  • Bascom Palmer Eye Institute
    Bascom Palmer Eye InstituteFellowship, 1996 - 1997
  • Massachusetts Eye and Ear Infirmary/Harvard Medical School
    Massachusetts Eye and Ear Infirmary/Harvard Medical SchoolResidency, Ophthalmology, 1993 - 1996
  • Massachusetts Eye and Ear Infirmary
    Massachusetts Eye and Ear InfirmaryClinical, Ophthalmology, 1993 - 1996
  • Massachusetts General Hospital
    Massachusetts General HospitalInternship, Internal Medicine, 1992 - 1993
  • Harvard Medical School
    Harvard Medical SchoolClass of 1992
  • Harvard College
    Harvard CollegeBachelor of Arts, 1984 - 1988

Certifications & Licensure

  • FL State Medical License
    FL State Medical License 2004 - 2026
  • IL State Medical License
    IL State Medical License 2002 - 2026
  • MA State Medical License
    MA State Medical License 2002 - 2026
  • MI State Medical License
    MI State Medical License 2002 - 2026
  • OH State Medical License
    OH State Medical License 1997 - 2026
  • PA State Medical License
    PA State Medical License 2002 - 2026
  • CA State Medical License
    CA State Medical License 2002 - 2025
  • American Board of Ophthalmology Ophthalmology
  • Join now to see all

Awards, Honors, & Recognition

  • Meaningful Use Stage 1 Certification Centers for Medicare & Medicaid Services, 2012
  • Lew R. Wasserman Merit Award Research to Prevent Blindness 2010
  • American Academy of Ophthalmology Senior Achievement Award (Senior Honor Award) 2008
  • Join now to see all

Clinical Trials

Publications & Presentations

PubMed

Journal Articles

  • HIV-1 coat protein increases intracellular Ca2+ and injures neurons: toxicity prevented by calcium channel antagonists.  
    Dreyer EB, Kaiser PK, Offermann JT, and Lipton SA., Science 1990
  • Neuronal injury due to HIV-1 envelope protein is blocked by anti-gp120 antibodies but not by anti-CD4 antibodies.  
    Kaiser PK, Offermann JT, and Lipton SA., Neurology 1990
  • VIP-mediated increase in cAMP prevents TTX-induced retinal ganglion cell death in vitro.  
    Kaiser PK and Lipton SA., Neuron 1990
  • Join now to see all

Books/Book Chapters

  • Join now to see all

Abstracts/Posters

  • A study of the effects of vasoactive intestinal peptide on natural cell death of retinal ganglion cells.
    Kaiser PK, Summa cum laude honors thesis; Harvard College
  • Vasoactive intestinal peptide via cAMP rescues mammalian retinal ganglion cells from tetrodotoxin-induced death.
    Kaiser PK and Lipton SA, Society for Neuroscience
  • Calcium channel antagonists partially prevent neuronal cell killing by HIV-1 coat protein gp120 in vitro.
    Campo R, Offermann JT, Arroyo JG, Kaiser PK, Chen HS V, and Lipton SA, Society for Neuroscience
  • Join now to see all

Lectures

  • New treatment strategies for corneal abrasions. 
    New England Ophthalmological Society Meeting, Boston, MA
  • Digital Journal of Ophthalmology and other world wide web resources for ophthalmologists. 
    American Academy of Ophthalmology Annual Meeting
  • Submacular Surgery Trials. 
    Cleveland Ophthalmology Society Meeting
  • Join now to see all

Press Mentions

  • New Framework for Deciding When to Operate on Patients with Epiretinal Membranes
    New Framework for Deciding When to Operate on Patients with Epiretinal MembranesNovember 11th, 2024
  • Cimerli Approved as Interchangeable Biosimilar to Lucentis
    Cimerli Approved as Interchangeable Biosimilar to LucentisAugust 3rd, 2022
  • FDA Approves Coherus’ CIMERLI™ (Ranibizumab-Eqrn) as the First and Only Interchangeable Biosimilar to Lucentis® for All Five Indications, with 12 Months of Interchangeability Exclusivity
    FDA Approves Coherus’ CIMERLI™ (Ranibizumab-Eqrn) as the First and Only Interchangeable Biosimilar to Lucentis® for All Five Indications, with 12 Months of Interchangeability ExclusivityAugust 2nd, 2022
  • Join now to see all

Grant Support

  • Vacsular Remodeling And Effects Of Angiogenic Inhibition In Diabetic RetinopathyNational Eye Institute2006
  • Vascular Remodeling And Effects Of Angiogenic InhibitionNational Eye Institute2005

Professional Memberships